ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CLRB Cellectar Biosciences Inc

4.03
0.395 (10.87%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1,769,204
Bid Price 4.00
Ask Price 4.06
News -
Day High 4.07

Low
1.30

52 Week Range

High
4.45

Day Low 3.79
Company Name Stock Ticker Symbol Market Type
Cellectar Biosciences Inc CLRB NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.395 10.87% 4.03 20:00:00
Open Price Low Price High Price Close Price Prev Close
3.83 3.79 4.07 3.98 3.635
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
8,021 1,769,204 $ 3.91 $ 6,913,008 - 1.30 - 4.45
Last Trade Time Type Quantity Stock Price Currency
19:59:55 6 $ 4.0492 USD

Cellectar Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
0 30.45M - 0 -28.6M - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Cellectar Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CLRB Message Board. Create One! See More Posts on CLRB Message Board See More Message Board Posts

Historical CLRB Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.804.173.533.841,134,3840.236.05%
1 Month4.004.453.353.861,131,5550.030.75%
3 Months2.894.452.553.531,867,6941.1439.45%
6 Months2.534.451.873.401,007,7491.5059.29%
1 Year1.484.451.303.14670,3002.55172.30%
3 Years1.676.75680.3372.18421,6912.36141.32%
5 Years2.166.75680.3372.04545,2871.8786.57%

Cellectar Biosciences Description

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.

Your Recent History

Delayed Upgrade Clock